Mammalian Transient Protein Expression Market Outlook 2031:
The mammalian transient protein expression market size was valued at USD 643.10 Million in 2022 and is projected to reach USD 1.39 Billion by 2031, expanding at a CAGR of 9% during the forecast period 2023 - 2031. The growth of the market is attributed to the increasing demand for biologics and proteomics and technological advancement due to the rising adoption of antibodies in research.
The most naturally structured and active mammalian proteins are those that are produced in mammalian host systems, which is the preferred expression platform. The best system for examining a specific protein's function in a physiologically appropriate condition is a mammalian expression because it enables the protein to function at its maximum level and to undergo the most posttranslational processing.
It is frequently utilized in antibodies and therapeutic protein production applications. Being open systems, protein expression systems allow the addition of a wide range of synthetic and natural components to the reaction medium such as detergents, tagged amino acids, regulatory proteins, and reducing/oxidizing agents, making them suitable for a range of proteomics research.
Recombinant proteins are complex, huge molecules with intricate and varied mechanisms. Since the chemical synthesis of proteins is highly challenging due to their size and complexity, recombinant proteins are created biologically using the protein synthesis machinery.
Factors such as regulatory approval, posttranslational changes, potential contamination from pathogenic microbes, protein yield, operational expenses, and production time are positive and negative sides of each production system. As a result, these factors create immense growth opportunities for the market players.
Covid-19 Impact
The Covid-19 pandemic negatively affected the global mammalian transient protein expression market. Lockdown across the globe, supply chain disorders, and oscillating supply of raw materials forced manufacturers to shut down production leading to an unfortunate decline in market growth. Launch of vaccines to combat the Covid-19 pandemic is expected to contribute to the market growth over the forecast period.
Mammalian Transient Protein Expression Market Dynamics
The market research report on the global mammalian transient protein expression market provides a detailed analysis by focusing on revenue growth, facts, figures, and historical data to determine major drivers, existing restraints, key opportunities, and competitive analysis. The report includes recent developments that can shape the overall performance of the market during the forecast period, 2023 to 2031.
Key Drivers: Increasing adoption of antibodies for research studies
Concerns regarding the applicability of current protein expression techniques are raised due to increased need for recombinant vaccine antigens and immunotherapeutic drugs. A small amount of expressed materials can be used in the manufacturing of vaccines, which fall into a fairly complex category with a variety of target antigens that have unique structural properties.
Furthermore, with the contamination and toxic-free approach, there is an increase in demand for mammalian transient protein expression. Mammalian transient protein expression system provides a low risk of contamination, as the chance of pollutants from outside materials is reduced by the low number of living bacteria or cells.
The deficiency of any nuclease activities ensures that linear DNA substrates remain consistent during protein synthesis and deliver all the desired components to generate a recombinant protein in vitro. The application of protein expression in applied biologics and genomics is projected to drive the global market in the coming years. These are the primary factors driving growth of the market.
Existing Restraints: High cost of manufacturing of mammalian cell-derived therapeutic
The mammalian transient protein expression market is estimated to be hampered by factors such as ethical issues, risk of contamination, and high cost. The high cost of producing therapeutic and commercial proteins obtained from mammalian cells, the potential for pathogenic contamination, and chemical toxicity in animal cell culture create serious biosafety issues and the risk for pathogenic contamination and chemical toxicity in animal cell culture creates serious biosafety issues.
The adoption of protein products obtained from mammals is reduced due to ethical issues surrounding the use of animal cell culture. These factors are estimated to impede market growth in the coming years. Another potential drawback of employing human cell lines is the risk of infection with human-specific viruses, however, this risk can be decreased by employing a number of viral inactivation or clearing techniques.
Additionally, despite the fact that human cell lines are presently used extensively in vaccine manufacturing, biopharmaceutical research, the development of several approved protein treatments, human cell lines have little clinical experience due to their new advent into protein manufacturing, which is anticipated to hamper the market growth.
Key Opportunities: Increasing prevalence of chronic illness
Rising prevalence of chronic diseases such as cancers, AIDS, hepatitis, and other infectious diseases, demand for biological treatments has increased generally because of an increase in the diagnostic population for various ailments. Typically, various immuno- and bio-therapeutic compounds are produced using mammalian cell lines.
A number of key manufacturers are concentrating on improving the productivity, flexibility, and throughput capacities as well as redefining the control productivity of protein production employing mammalian cell lines. Additionally, a small number of global and regional companies have significantly turned their attention to the manufacturing of reagent supplies and their associated diagnostic applications.
The development of in-vitro diagnostics tools, equipment, and expression vector systems differs depending on the industrial specialty. Investments in the R&D and technological developments of expression systems, molecular agents, diagnostic tools, and kits are projected to create immense growth opportunities during the forecast period.
For instance, in September 2021, Promega Corporation introduced the OncoMate MSI Dx Analysis System in vitro diagnostic in the U.S. enabling a new method for pathologists and oncologists to check for Lynch syndrome in patients with colorectal cancer.
In August 2021, the US Food and Drug Administration (FDA) authorized OncoMate MSI as an IVD medical device to test the state of microsatellite instability (MSI) in tumors including colorectal cancer. These factors are projected to offer lucrative opportunities for market growth.
Scope of the Mammalian Transient Protein Expression Market Report
The report on the global mammalian transient protein expression market includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Mammalian Transient Protein Expression Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023 – 2031
|
|
Segmentation
|
Products (Reagents & Consumables, Expression Vector, Instruments, and Cell Lines [Human Embryonic Kidney 293 (HEK 293) Cells and Chinese Hamster Ovary Cells (CHO)]), Applications (Academic Research, Functional Cell-Based Assays, Bio-production [Therapeutic protein production and Antibody Production], and Others), End-users (Academic & Research Institutes, Biopharmaceutical Companies, and Contract Research Organization)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Agilent Technologies, Inc.; Bio-Rad; HiMedia Laboratories.; Lonza; Merck KGaA; Mirus; Promega Corporation; Qiagen; Sino Biological, Inc.; Takara Bio; and Thermofisher Scientific.
|
Mammalian Transient Protein Expression Market Segment Insights
The reagents & consumables segment accounted for a major market share in 2021
Based on products, the mammalian transient protein expression market is segregated into reagents & consumables, expression vector, instruments, and cell lines. The cell line segment is further fragmented into human embryonic kidney 293 (HEK 293) cells and Chinese hamster ovary cells (CHO).
The reagents & consumables segment accounted for a market share of around 34% in 2021. The introduction of efficient and cost-effective transfection reagents including polyethyleneimine enables an effective method for producing proteins and biologics using mammalian cell cultures.
The bio-production segment is projected to expand at a high CAGR during the forecast period
On the basis of applications, the mammalian transient protein expression market is fragmented into academic research, functional cell-based assays, bio-production, and others. The bio-production segment is further bifurcated into therapeutic protein production and antibody production. The bio-production segment held around 41% of the total revenue share in 2021.
Nowadays, therapeutic proteins need to be produced in large quantities for the treatment of diseases that impact millions of people. Recombinant proteins can be produced and used as drugs, vaccines, and diagnostic tools due to recent developments in recombinant DNA technology. Recombinant proteins are predominantly produced using prokaryotic and eukaryotic expression host systems, for a variety of uses such as mammalian cells both in small and large-scale settings. The development of effective bioprocessing methods is essential for the commercial production of therapeutic recombinant proteins.
The biopharmaceutical companies segment is anticipated to grow at a rapid pace during the projected period
In terms of end-users, the global market is divided into academic & research institutes, biopharmaceutical companies, and contract research organizations. The biopharmaceutical companies segment is anticipated to grow at a rapid pace during the projected period.
Mammalian cell expression has emerged as the predominant method for producing recombinant proteins for clinical uses because it allows for post-translational modification and the building of molecular structures that resemble those of human proteins.
North America dominated the market in 2021
On the basis of regions, the global market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2021. The U.S held around 90% of the total market share in 2021 and is projected to expand at a rapid pace during the forecast period owing to rising incidence of cancer and other chronic diseases in the country.
According to the CDC, colorectal cancer is the fourth most prevalent disease in the country. As funding and government support for research in numerous fields increases, the mammalian transient protein expression market is expected to boost.
The mammalian transient protein expression market in Europe is anticipated to grow at a rapid pace during the forecast period. The market in Germany is projected to expand at a CAGR of around 9% during the projected period.
Recombinant cell culture is estimated to be in high demand due to increasing contract research manufacturing and R&D activities in the country. Companies and research institutions in Germany and the UK have a significant pipeline in therapeutic areas including cancer.
Asia Pacific is estimated to hold a key market share during the forecast period. China accounts for around 25% of the total market share in 2021 and is estimated to expand at a CAGR of around 9% during the projected period. Contract research work is primarily conducted in China. The use of recombinant cell culture media additives is on the rise due to increasing drug discovery and research activity in China.
One of the major biopharmaceutical sectors in the world is situated in China. Furthermore, there are numerous domestic pharmaceutical companies in China. Furthermore, the Chinese government supports ongoing research in the life sciences.
Segments
The global mammalian transient protein expression market has been segmented on the basis of
Products
- Reagents & Consumables
- Expression Vector
- Instruments
- Cell Lines
- Human Embryonic Kidney 293 (HEK 293) Cells
- Chinese Hamster Ovary Cells (CHO)
Applications
- Academic Research
- Functional Cell-Based Assays
- Bio-production
- Therapeutic protein production
- Antibody Production
- Others
End-users
- Academic & Research Institutes
- Biopharmaceutical Companies
- Contract Research Organization
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key companies operating in the mammalian transient protein expression market include Agilent Technologies, Inc.; Bio-Rad; HiMedia Laboratories.; Lonza; Merck KGaA; Mirus; Promega Corporation; Qiagen; Sino Biological, Inc.; Takara Bio; and Thermofisher Scientific. Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance,
- In April 2022, Gibco CTS TrueCut Cas9 Protein was launched by Thermo Fisher Scientific, which was produced according to GMP standards.
- In October 2020, an expansion of Merck KgaA was announced with the inauguration of a new membrane manufacturing unit in Darmstadt, Germany. The objective was to expand the manufacturing of Millipore Express® membranes, which help biological medicine products stay sterile.
Request For Customization
Enquiry Before Buying
Speak With Analyst
